University of Freiburg
60
5
6
37
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.7%
1 terminated/withdrawn out of 60 trials
97.4%
+10.9% vs industry average
10%
6 trials in Phase 3/4
3%
1 of 37 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (60)
Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities
Role: lead
Cross-cultural Adaptation and Translation Validation of the iADH Universal Case Mix Tool (UCMT).
Role: collaborator
Using Digital Twin Technology and Clinical Decision Support Systems to Improve the Early Detection, Personalised Treatment, and Long-term Monitoring of Patients Across the Full Spectrum of Metabolic-associated Fatty Liver Disease (MAFLD).
Role: collaborator
Rationale for New Topical Anthroponotic Cutaneous Leishmaniasis (ACL) Treatment in Kabul
Role: collaborator
Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein
Role: lead
Evaluation of a LAMP Assay for T. Pallidum. Pertenue
Role: collaborator
Combination of Hypothermia and Thrombectomy in Acute Stroke
Role: lead
Analysis of Intestinal Defensin Expression in Acute GVHD
Role: lead
Spinal CSF Leaks in Chronic Subdural Hematoma
Role: lead
Analysis of CMTM6 Expression in Patients With Acute Myeloid Leukemia
Role: lead
Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus
Role: collaborator
Intestinal Biomarker Analysis After ECP for ICI Colitis
Role: lead
Munich Long COVID Registry for Children, Adolescents, and Adults
Role: collaborator
Cellular Stress Reactions During Graft-versus-host Disease
Role: lead
Treatment of Patients With Teduglutide (GLP-2) for GVHD and Analysis of Paneth Cells of GVHD Patients
Role: lead
The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors
Role: lead
ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment
Role: lead
Multicenter Study Using IMC to Analyze the Impact of ICANS on Microglia
Role: lead
Improved Self-management for Patients on Ventricular Assist Device (VAD) Support - Phase 3
Role: lead
Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents
Role: lead